Regeneron Pharmaceuticals Q4 Adj. EPS $7.5 Beats $6.9 Estimate, Sales $2.17B Beat $2.11B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $7.5 per share which beat the analyst consensus estimate of $6.9 by 8.7 percent. This is a 9.65 percent increase over earnings of $6.84 per share

Benzinga · 02/06/2020 11:32

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $7.5 per share which beat the analyst consensus estimate of $6.9 by 8.7 percent. This is a 9.65 percent increase over earnings of $6.84 per share from the same period last year. The company reported quarterly sales of $2.17 billion which beat the analyst consensus estimate of $2.11 billion by 2.84 percent. This is a 12.55 percent increase over sales of $1.928 billion the same period last year.